131052-36-3

Usage

Uses

Used in Pharmaceutical Applications:
1-(1-methyl-1H-tetrazol-5-yl)methanamine is used as a therapeutic agent for the diagnosis and treatment of certain mental illnesses. It was historically employed to induce seizures as part of the treatment process, although its use has diminished due to the risks associated with convulsions.
Used in Anti-Epileptic Research:
In the field of anti-epileptic drug development, 1-(1-methyl-1H-tetrazol-5-yl)methanamine serves as a potential candidate for the creation of new medications. Its properties have been studied to understand its potential as an anti-epileptic drug, aiming to provide better treatment options for patients suffering from epilepsy and seizure disorders.
Used in Neuroscience Research:
1-(1-methyl-1H-tetrazol-5-yl)methanamine is used as a research tool in neuroscience to study the mechanisms of seizure induction. It helps researchers explore the effects of seizures on the brain, contributing to a deeper understanding of epilepsy and seizure disorders, and potentially leading to the development of more effective treatments.
Used in Chemical Research:
As a chemical compound, 1-(1-methyl-1H-tetrazol-5-yl)methanamine may also be utilized in various chemical research applications, where its unique properties can be explored for the development of new compounds or to understand specific chemical reactions and interactions.

Upstream product

• 131052-35-2 2-[(1-methyl-1H-tetrazol-5-yl)methyl]isoindoline-1,3-dione 

Relevant academic research and scientific papers

A Convenient One-Pot Synthesis of 1,5-Disubstituted Tetrazoles Containing an Amino or a Carboxy Group

Abstract: A convenient method is proposed for constructing the tetrazole ring by a one-pot reaction of amides with phosphorus oxychloride and sodium azide. A series of 1,5-disubstituted tetrazoles containing an amino or a carboxy group, which present interest as buildings blocks for the synthesis of biologically active substances, were obtained.

PYRIDAZINONE DERIVATIVES AND USE THEREOF AS P2X7 RECEPTOR INHIBITORS

Novel pyridazinone compounds of formula (I), which inhibit the purinergic P2X7 receptor and are useful for prevention, therapy and improvement of inflammatory and immunological diseases.

Biologically active amides

Novel peptide compounds of the formula are provided together with their acid addition salts and their complexes with pharmaceutically acceptable metals. The compounds are LH-RH analogues and together with their salts and complexes exhibit LH-RH antagonist activity. In the formula X1 is selected from pyroglutamyl, a group V1 -Pro- where V1 is acyl, alkyloxycarbonyl or aralkyloxycarbonyl, and a group V2 --CO-- where V2 is cycloalkyl; X2 is selected from histidyl and a direct bond; X3 is selected from phenylalanyl optionally substituted in the benzene ring and tryptophyl; X4 is selected from glycyl, seryl, alanyl (D- or L), D-leucyl and D-valyl; X5 is phenylalanyl optionally substituted in the benzene ring; X6 is selected from glycyl, alanyl (D- or L-), D-leucyl and D-valyl; X7 is selected from phenylalanyl optionally substituted in the benzene ring and leucyl; X8 is a direct bond when X2 is histidyl and is otherwise arginyl or homoarginyl; and W is selected from glycine amide and a group --NR1 R2 where R1, R2 and the nitrogen atom together comprise a group selected from amino, N-alkylamino, N,N-dialkylamino, pyrrolidino, morpholino and 1-methyl-5-aminomethyltetrazolyl, the `alkyl` having from 1 to 4 carbon atoms and being optionally substituted by an hydroxyl group, provided that, when X1, X3, X4, X5, X7 and X8 are respectively pyroglutamyl, tryptophyl, seryl, tyrosyl, leucyl and arginyl, W is other than glycine amide or N-ethylamino when X6 is glycyl and is other than glycine amide when X6 is D-alanyl. All references are to the L-amino acids and their radicals except in the case of glycine and unless otherwise stated. Also provided are methods for the preparation of the peptides, salts and complexes, pharmaceutical formulations containing them and methods for the preparation of such formulations, and methods for the use of the peptides, salts and complexes in human and in veterinary medicine.